Merck’s oral HIV treatment meets main goal in late-stage study
Merck (MRK.N), opens new tab said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial.
The company said the treatment is a once-daily two-drug regimen of doravirine/islatravir that was non-inferior to a three-drug regimen in adults with HIV-1 infection who had not previously received antiretroviral therapy.
The Rahway, New Jersey-based company plans to present detailed findings from this trial at a future medical meeting and to submit applications including these data to health authorities.
